Abstract: Provided is a method for preventing or treating a liver disease, including administering a therapeutically effective amount of pharmaceutical composition to a subject in need, and the pharmaceutical composition includes the isothiocyanate structural modified compound and a pharmaceutically acceptable carrier thereof.

Abstract: An optical system affixed to an electronic apparatus is provided, including a first optical module, a second optical module, and a third optical module. The first optical module is configured to adjust the moving direction of a first light from a first moving direction to a second moving direction, wherein the first moving direction is not parallel to the second moving direction. The second optical module is configured to receive the first light moving in the second moving direction. The first light reaches the third optical module via the first optical module and the second optical module in sequence. The third optical module includes a first photoelectric converter configured to transform the first light into a first image signal.

Abstract: A pharmaceutical composition for treating disorders associated with insulin resistance is disclosed, and the composition comprises at least one inhibitor which is an effective agent to suppress endothelin-1-stimulated resistin gene expression through decreasing the endothelin-1-stimulated phosphorylation of proteins downstream of endothelin type A receptor, wherein the downstream signaling molecules comprise ERK1/2, JNKs, AKT, and STAT3 proteins, and wherein the inhibitor is selected from at least one antagonist of the endothelin type A receptor or downstream signaling proteins.

Abstract: A method for detecting fat-reducing compounds comprises four steps, the first step is to provide a clone of adipocytes cultured on a culture dish; the second step is to add a dilution of a test compound to the culture dish for a first time; the third step is to add an insulin-like growth factor to the culture dish for a second time; and the fourth step is to collect the adipocytes for detecting the expression level of at least one specific protein to be a reference value for reducing fat or for decreasing the glucose transport by the test compound. A further method for detecting fat-reducing compounds is disclosed by modifying the last step which detects the levels of a particular protein translocated from the cytosol to the cell membrane of the adipocytes for testing whether the compounds have the ability to regulate or reduce adipocyte glucose uptake.

Abstract: A method for reducing food intake in a subject and a method for reducing the levels of an endocrine in a subject. The methods include administering to the subject in need thereof an effective amount of a compound of the formula: Also disclosed is a liposomal preparation which includes a liposome and a compound entrapped therein. The entrapped compound is of the formula shown above.

Abstract: A method for reducing food intake in a subject and a method for reducing the levels of an endocrine in a subject comprising administering to the subject in need thereof an effective amount of a compound of the formula: wherein A is alkenyl, and each of Ra, Rb, Rc and Rd is herein defined.

Abstract: A method for reducing food intake in a subject and a method for reducing the levels of an endocrine in a subject.